← Back to Screener
Gain Therapeutics, Inc. Common Stock (GANX)
Price$2.12
Favorite Metrics
Price vs S&P 500 (26W)-0.63%
Price vs S&P 500 (4W)-0.26%
Market Capitalization$89.98M
All Metrics
Book Value / Share (Quarterly)$0.44
P/TBV (Annual)6.71x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.44
Price vs S&P 500 (YTD)-37.99%
Net Profit Margin (TTM)-6393.75%
EPS (TTM)$-0.65
10-Day Avg Trading Volume0.58M
EPS Excl Extra (TTM)$-0.65
EPS (Annual)$-0.89
ROI (Annual)-262.42%
Net Profit Margin (5Y Avg)-15801.64%
Cash / Share (Quarterly)$0.50
ROA (Last FY)-168.36%
EBITD / Share (TTM)$-0.61
ROE (5Y Avg)-129.19%
Operating Margin (TTM)-6506.25%
Cash Flow / Share (Annual)$-0.44
P/B Ratio4.85x
P/B Ratio (Quarterly)6.67x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)434.62x
Net Interest Coverage (TTM)-230.50x
ROA (TTM)-155.11%
EPS Incl Extra (Annual)$-0.89
Current Ratio (Annual)6.63x
Quick Ratio (Quarterly)6.46x
3-Month Avg Trading Volume1.10M
52-Week Price Return22.41%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.44
P/S Ratio (Annual)1630.58x
Asset Turnover (Annual)0.00x
52-Week High$4.34
Operating Margin (5Y Avg)-15704.40%
EPS Excl Extra (Annual)$-0.89
CapEx CAGR (5Y)17.60%
26-Week Price Return8.12%
Quick Ratio (Annual)6.46x
13-Week Price Return-3.18%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)6.63x
Enterprise Value$69.539
Asset Turnover (TTM)0.01x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-40210.67%
Cash / Share (Annual)$0.50
3-Month Return Std Dev118.21%
Net Income / Employee (TTM)$-1
ROE (Last FY)-278.10%
Net Interest Coverage (Annual)-21.27x
EPS Basic Excl Extra (Annual)$-0.89
Receivables Turnover (TTM)0.41x
Total Debt / Equity (Quarterly)0.02x
EPS Incl Extra (TTM)$-0.65
Receivables Turnover (Annual)0.72x
ROI (TTM)-270.08%
P/S Ratio (TTM)562.35x
Pretax Margin (5Y Avg)-15753.38%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.44
Price vs S&P 500 (52W)-12.68%
Year-to-Date Return-33.85%
5-Day Price Return13.90%
EPS Normalized (Annual)$-0.89
ROA (5Y Avg)-86.78%
Net Profit Margin (Annual)-40354.33%
Month-to-Date Return9.79%
Cash Flow / Share (TTM)$-1.43
EBITD / Share (Annual)$-0.89
Operating Margin (Annual)-40328.25%
LT Debt / Equity (Annual)0.02x
ROI (5Y Avg)-122.56%
LT Debt / Equity (Quarterly)0.02x
EPS Basic Excl Extra (TTM)$-0.65
P/TBV (Quarterly)6.71x
P/B Ratio (Annual)6.67x
Pretax Margin (TTM)-6375.00%
Book Value / Share (Annual)$0.44
Price vs S&P 500 (13W)-6.05%
Beta0.21x
Revenue / Share (TTM)$0.00
ROE (TTM)-289.11%
52-Week Low$1.41
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.27
4.27
4.27
4.27
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GANXGain Therapeutics, Inc. Common Stock | 562.35x | — | — | — | $2.12 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Gain Therapeutics is a clinical-stage biotech company developing novel small molecule therapeutics using its proprietary Magellan platform, which identifies allosteric binding sites on disease-implicated proteins. The company's lead program, GT-02287, targets GBA1 Parkinson's disease, with a broader pipeline addressing lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. Gain operates globally across Switzerland, Spain, the United States, and Australia.